XML 57 R48.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholder's Equity - Additional Information (Details) - USD ($)
9 Months Ended
Aug. 04, 2023
May 17, 2023
Mar. 30, 2021
Sep. 30, 2023
Sep. 30, 2022
Jan. 01, 2023
Dec. 31, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Number of shares reserved for issuance       3,264,419      
Weighted-average fair value of the stock options granted       $ 2.25      
Total unrecognized stock-based compensation balance for unvested options       $ 13,400,000      
Total unrecognized stock-based compensation balance for unvested options expected to be recognized period       2 years 3 months 18 days      
Aggregate intrinsic value of options exercised       $ 59,300 $ 1,200,000    
Preferred stock, shares issued       0     0
Shares of common stock       44,104,672     36,257,493
Maximum              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Percenatage of originally issued series A preferred stock       30.00%      
Series A Preferred Stock              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Redemption value of outstanding preferred stock       $ 18,000,000      
Preferred stock, redemption price per share       $ 4.33      
Common stock beneficial ownership, percentage 9.99%            
Pionyr Immunotherapeutics, Inc              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Shares of common stock 1,800,652            
Percentage of acquired of outstanding equity 100.00%            
Pionyr Immunotherapeutics, Inc | Nonvoting Common Stock [Member]              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Shares of common stock 153,121            
Pionyr Immunotherapeutics, Inc | Series A Preferred Stock              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Preferred stock, shares issued 4,153,439            
Common Stock | Pionyr Immunotherapeutics, Inc              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Common stock issuable upon the conversion 4,153,439            
Common Stock | URO              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Company issued and sold shares of common stock   6,110,000          
Public offering price   $ 6.55          
Net proceeds received after deducting commissions and other offering expenses   $ 37,400,000          
2021 Stock Incentive Plan              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Number of shares reserved for issuance           1,450,299  
2021 Employee Stock Purchase Plan              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Plan effective date     Mar. 30, 2021        
Increase in number of shares reserved and available for issuance as percentage on common stock outstanding       1.00%      
Number of shares purchased by employees       0      
2021 Employee Stock Purchase Plan | Common Stock              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Number of shares issued for purchase       346,613